Flotek Industries heads into its May 6 Q1 earnings report with short sellers firmly committed but options traders leaning the other way — a genuine split in how the market is positioned.
Short interest is the headline concern. Nearly 7.5% of Flotek's free float is currently sold short, a level that has climbed roughly 10% over the past month even as it eased slightly in the last week. Days to cover run above 11, meaning shorts would need nearly two weeks of average volume to exit. The ORTEX short score is running at 76.2 — a reading that places the stock in the most-shorted tier of the universe — and has barely budged over the past two weeks despite a modest drop in shares short. Borrow cost has eased from above 0.9% in mid-March to around 0.65% today, reflecting looser conditions in the lending market; availability has also widened as the lending pool opens up, pulling back from peaks seen in late March when the 52-week utilization high of 69.5% was recorded.
Options positioning tells a markedly different story. Call activity is dominating the tape in a way that is unusual for this stock. The put/call ratio is running at just 0.21 — well below its 20-day average of 0.27 and close to the 52-week low of 0.08 — suggesting traders are reaching for upside exposure rather than downside protection into the print. That bullish tilt in options contrasts sharply with the persistent short interest load and frames the earnings event as a genuine tug of war between two camps.
The ownership structure adds important context. ProFrac Holding Corp. commands 58% of shares outstanding — a controlling stake that limits the freely tradeable float and amplifies the effect of any positioning shifts. Driehaus Capital, a momentum-oriented manager, built a near-complete position in FTK during 2025, adding 825,000 shares. On the insider side, the CEO and CFO both sold small parcels in February at around $16, immediately following share award grants — a pattern more consistent with routine compensation management than conviction selling. The stock closed at $16.86 on May 5, up just over 1% on the day but essentially flat on the week, and up roughly 5% over the past month.
The analyst picture is thin and largely dated. Northland Capital Markets reiterated an Outperform with a $20 target in December 2025, which sits above the current price but reflects a view formed several months ago. The mean target of $21.25 implies roughly 26% upside from current levels, though coverage is sparse and the most recent action is now more than 40 days old. The EV/EBITDA multiple at roughly 11x has compressed about half a turn over 30 days, suggesting the market has been quietly derating the stock even as the price has edged higher.
The Q1 print will test whether the company's revenue and margin trajectory can justify the options market's bullish lean — or confirm the short sellers' more cautious read on the fundamental story.
See the live data behind this article on ORTEX.
Open FTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
